BioCentury
ARTICLE | Top Story

Lexicon gains on Phase III carcinoid syndrome data

August 4, 2015 12:52 AM UTC

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) surged $5.16 (61%) to $13.60 on Monday, bringing the company's market cap to $1.4 billion, after telotristat etiprate met the primary endpoint in the Phase III TELESTAR trial to treat carcinoid syndrome. The company plans to submit an NDA to FDA in 1Q16.

Patients received 250 or 500 mg of oral telotristat etiprate thrice daily for 12 weeks. Both doses led to a statistically significant reduction from baseline vs. placebo in the average number of daily bowel movements (p<0.001). ...